Immune response to hepatitis B vaccine in premature neonates.

Southeast Asian J Trop Med Public Health

Department of Pediatrics, Bangkok Christian Hospital, Thailand.

Published: March 1991

The immunogenecity of a recombinant yeast-derived hepatitis B vaccine in 25 premature infants who were born to HBsAg negative mothers was studied. The gestational ages were 28-37 weeks and birth weights were 1300-2000 grams. Seroconversion occurred in 22 infants, the anti HBs titers varied between 50 and 13,470 IU/L (Geometric mean titer = 542 IU/L). Seroconversion rate = 88%. The response did not vary with gestational age, birth weight or illness status.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hepatitis vaccine
8
vaccine premature
8
immune response
4
response hepatitis
4
premature neonates
4
neonates immunogenecity
4
immunogenecity recombinant
4
recombinant yeast-derived
4
yeast-derived hepatitis
4
premature infants
4

Similar Publications

Introduction: 58 million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development.

View Article and Find Full Text PDF

Objectives: To evaluate the impact of a comprehensive intervention using nursing-sensitive quality indicators on pregnant women with hepatitis B and their newborns.

Design: A randomized controlled monocentric trial conducted from January 2020 to May 2022. Participants/Materials: 80 pregnant women diagnosed with hepatitis B were randomly assigned to either a control group (n=40) or an experimental group (n=40).

View Article and Find Full Text PDF

Background: Patients with end stage renal disease (ESRD) undergoing hemodialysis are at increased risk for infection and impaired vaccination responses. We analyzed overlap and influencing factors of vaccination responses against severe acute respiratory syndrome corona virus disease 2 (SARS-CoV-2) and Hepatitis B virus (HBV).

Methods: SARS-CoV-2 and HBV vaccination response was assessed in a cohort of German ESRD hemodialysis patients.

View Article and Find Full Text PDF

While Hepatitis A Virus (HAV) vaccination in global immunization programs has shown a virtual elimination of the disease within few years of the vaccination program, changing epidemiological landscape in India underscores the need for evidence-based, updated guidance on immunization practices. In May 2024, a panel of 15 distinguished opinion leaders and an organizing committee convened for an intensive, face-to-face advisory board meeting on high burden of HAV infection among adults, increased mortality rate in adolescents, symptomatic presentation in children, and evolving landscape globally and within India. Extensive comparable deliberations on long-term follow-up data from India and data from country of origin advocated immunogenicity, tolerability, and long-term protective effects of single-dose live attenuated HAV vaccine in children.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!